Lv3
320 积分 2022-01-06 加入
Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class
8小时前
待确认
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
8小时前
已完结
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial
11天前
已完结
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: Phase 3 LEAP-006 Study
11天前
已完结
Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
12天前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
27天前
已完结
First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions
27天前
已完结
Toward personalized treatment approaches for non-small-cell lung cancer
27天前
已完结
Non-small-cell lung cancer
27天前
已完结
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
